89bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ETNB research report →
Range $12 – $25
Price Chart
About the company
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH).
- CEO
- Rohan Palekar
- IPO
- 2019
- Employees
- 93
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on ETNB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.20B
- P/E
- -12.37
- Fwd P/E
- 66.70
- PEG
- 0.21
- P/S
- 0.00
- P/B
- 4.49
- EV/EBITDA
- -11.59
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -32.43%
- ROIC
- -33.96%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-38,000+86.1%
- Op Income
- $-384,656,000
- Net Income
- $-367,079,000-158.2%
- EPS
- $-3.51-75.5%
- OCF Growth
- -184.7%
- FCF Growth
- -184.7%
- 52W High
- $15.06
- 52W Low
- $4.16
- 50D MA
- $12.41
- 200D MA
- $9.75
- Beta
- 1.26
- RSI (14)
- 77
- Avg Volume
- 5.39M
No earnings-call transcripts are available for ETNB yet.
- Free Float
- 98.5%
- Shares Outstanding
- 148.30M
- Float Shares
- 146.01M
of shares held by institutions
202 13F filers
Buy/sell ratio 0.07. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Nuveen Asset Management, LLC | 286.49K | ▼ 3.42K |
| Point72 Asia (Singapore) Pte. Ltd. | 66.90K | ▲ 66.90K |
| Point72 (Difc) Ltd | 3.99K | ▲ 3.99K |
| Point72 Europe (London) Llp | 393 | ▲ 393 |
Held by 3 ETFs
Biggest fund positions in ETNB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 45,150 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 12,500 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 56,400 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 7,000 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 7,000 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 27,400 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 335,364 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 4,331,081 |
| Oct 30, 25 | RA CAPITAL MANAGEMENT, L.P. | sell | 25,000 |
| Oct 30, 25 | LAPORTE KATHLEEN | sell | 45,150 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ETNB coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ETNB?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
3 Investable Laggards In An Overbought Market
seekingalpha.com · Oct 28
My Top 3 Pharma Stocks
seekingalpha.com · Oct 20
89bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
businesswire.com · Oct 6
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 89bio, Inc. (NASDAQ: ETNB)
prnewswire.com · Sep 23
3 Potential Biotech Acquisition Targets
seekingalpha.com · Sep 19
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
businesswire.com · Sep 19
Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push
benzinga.com · Sep 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.